Skip to main content

Table 3 Differences between treatments (ratio for FEV1 and FVC, absolute values for other variables) for spirometric and other parameters

From: Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: Phase III study results

Variable 9 μg vs. Placebo (p-value) 4.5 μg vs. Placebo (p-value) 9 μg vs. 4.5 μg
(p-value)
60-min post-dose FEV1, L 1.11 (< 0.001) 1.11 (< 0.001) 1.01 (0.643)
Pre-dose FEV1, L 1.04 (0.002) 1.04 (0.002) 1.00 (0.955)
5-min post-dose FEV1, L 1.09 (< 0.001) 1.09 (< 0.001) 1.00 (0.984)
60-min post-dose FVC, L 1.07 (< 0.001) 1.07 (< 0.001) 0.99 (0.642)
Pre-dose FVC, L 1.02 (0.135) 1.03 (0.026) 0.99 (0.483)
5-min post-dose FVC, L 1.07 (< 0.001) 1.07 (< 0.001) 1.00 (0.982)
Morning PEF, L/min 15.30 (< 0.001) 12.86 (< 0.001) 2.45 (0.360)
Evening PEF, L/min 13.78 (< 0.001) 10.85 (< 0.001) 2.93 (0.260)
Night-time awakening, score/day -0.09 (0.038) -0.10 (0.020) 0.01 (0.816)
Breathlessness, score/day -0.17 (0.002) -0.18 (0.001) 0.01 (0.822)
Cough, score/day -0.13 (0.013) -0.12 (0.023) -0.01 (0.809)
Total symptom score -0.41 (0.001) -0.62 (0.001) -0.25 (0.883)
Use of salbutamol, inhalations/day -0.55 (< 0.001) -0.27 (0.027) -0.27 (0.029)
SGRQ total score -4.45 (0.001) -3.74 (0.001) -0.71 (0.553)